Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology
Martin S. Tallman(Memorial Sloan Kettering Cancer Center), Eunice S. Wang, Jessica K. Altman(Robert H. Lurie Comprehensive Cancer Center of Northwestern University), Frederick R. Appelbaum(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Vijaya Raj Bhatt(Susan Thompson Buffett Foundation), Dale L. Bixby(University of Michigan), Steven Coutré(Cancer Institute (WIA)), Marcos de Lima(Cleveland Clinic), Amir T. Fathi(Massachusetts General Hospital), Melanie Fiorella(University of California San Diego), James M. Foran, Aric C. Hall(University of Wisconsin Carbone Cancer Center), Meagan A. Jacoby(Barnes-Jewish Hospital), Jeffrey E. Lancet(Moffitt Cancer Center), Thomas W. LeBlanc(Cancer Institute (WIA)), Gabriel N. Mannis(Cancer Institute (WIA)), Guido Marcucci(City Of Hope National Medical Center), Michael G. Martin(St. Jude Children's Research Hospital), Alice S. Mims(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Margaret O’Donnell(City Of Hope National Medical Center), Rebecca L. Olin(UCSF Helen Diller Family Comprehensive Cancer Center), Deniz Peker(University of Colorado Cancer Center), Alexander E. Perl(University of Pennsylvania), Daniel A. Pollyea(University of Colorado Cancer Center), Keith W. Pratz(Sidney Kimmel Comprehensive Cancer Center), Thomas Prébet(Smilow Cancer Hospital), Farhad Ravandi(The University of Texas MD Anderson Cancer Center), Paul J. Shami(University of Utah), Richard M. Stone(Dana-Farber Brigham Cancer Center), Stephen A. Strickland(Breast Cancer Research Foundation), Matthew J. Wieduwilt(University of California San Diego), Kristina M. Gregory(National Comprehensive Cancer Network), OCN(National Comprehensive Cancer Network), Lydia J. Hammond(National Comprehensive Cancer Network), Ndiya Ogba(National Comprehensive Cancer Network)
Cited by 422
Abstract
Acute myeloid leukemia (AML) is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths due to leukemias in the United States. Recent advances have resulted in an expansion of treatment options for AML, especially concerning targeted therapies and low-intensity regimens. This portion of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for AML focuses on the management of AML and provides recommendations on the workup, diagnostic evaluation and treatment options for younger (age <60 years) and older (age ≥60 years) adult patients.
Related Papers
No related papers found
Powered by citation graph analysis